Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Plecanatide · Trulance Immediate Release

Peptide · Agonist of guanylate cyclase-C (GUCY2C) · developed by Salix

Approved FDA, Jan 2017
BHC Developer
1 Registered trials

What is Plecanatide?

Plecanatide is a structural analog of human uroguanylin that acts as a guanylate cyclase-C agonist. It binds GC-C on the intestinal epithelium, increasing intracellular and extracellular cGMP to stimulate chloride and bicarbonate secretion via CFTR, accelerate intestinal transit, and reduce visceral pain signaling.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Trulance Immediate Release
Drug type
Peptide
Targets
guanylate cyclase-C (GUCY2C), cystic fibrosis transmembrane conductance regulator (CFTR) (secondary target)
Mechanism
Agonist of guanylate cyclase-C (GUCY2C)
Pathways
cGMP signaling, chloride and bicarbonate secretion, intestinal fluid secretion
Therapy area
Gastroenterology
Developer
Salix (BHC)
FDA status
Approved as Trulance Immediate Release (January 19, 2017), NDA208745 · FDA label
UNII
7IK8Z952OK

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 4, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07723924 Phase 2 Functional Constipation (FC) Recruiting BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Functional Constipation (FC)

Other drugs acting on GUCY2C

Linaclotide FDA approved

More from Salix

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Plecanatide

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.